Acurx Pharmaceuticals, Inc.
ACXPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ibezapolstat | Phase 2 | Clostridium Difficile Infection | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Acurx Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Acurx Pharmaceuticals, Inc.'s (ACXP) pipeline across Phase 2. Its lead program is Ibezapolstat (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acurx Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Acurx Pharmaceuticals, Inc. (ACXP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACXP biotech catalysts?→
Add ACXP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acurx Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.